A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study

Yusuke Chihara, Takayuki Takeda, Yasuhiro Goto, Yoichi Nakamura, Yuko Tsuchiya-Kawano, Akira Nakao, Keisuke Onoi, Makoto Hibino, Minoru Fukuda, Ryoichi Honda, Takahiro Yamada, Ryusuke Taniguchi, Sinjiro Sakamoto, Koji Date, Seiji Nagashima, Shigeru Tanzawa, Koichi Minato, Koichi Nakatani, Miiru Izumi, Takayuki ShimoseJunji Kishimoto, Junji Uchino, Koichi Takayama

研究成果: ジャーナルへの寄稿学術誌査読

6 被引用数 (Scopus)

フィンガープリント

「A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science